- Conditions
- Cancer Survivor, Prevention of Human Papillomavirus Infection
- Interventions
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58), laboratory biomarker analysis, survey administration, medical chart review
- Biological · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 9 Years to 26 Years
- Enrollment
- 1,499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced May 22, 2026, 2:45 AM EDT